diabetes and obesity News
-
GI Dynamics Announces Approval of the I-STEP Clinical Study in India
BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India. I-STEP is a multi-center, randomized, pivotal study evaluating the safety and ...
-
GI Dynamics Announces the Presentation of Updated Data Sets at the 2022 Meeting of the American Diabetes Association
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide ...
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a ...
-
EPA, NIEHS Leaders Celebrate Children`s Health Month, 15 Years of Children`s Health Research
Tuesday, October 29th, U.S. Environmental Protection Agency (EPA)Administrator Gina McCarthy and National Institute of Environmental Health Sciences (NIEHS) Director Linda Birnbaum will kick off a conference celebrating 15 years of children's health research. The conference will highlight the progress made over more than a decade of children's research and the benefits of a more sustainable and ...
-
Sodexo health and wellness: embracing meatless mondays
Sodexo Blog - Health & Wellness by Chris Elam Here at Meatless Monday, we’re delighted that Sodexo is embracing the Meatless Monday movement in your client facilities around the country. We’re particularly pleased that you’ve chosen to focus on the health & wellness benefits, in line with your Better Tomorrow Plan, because it’s holistic changes which can improve ...
By 3BL Media
-
Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesity
BACKGROUND: Pulse wave velocity (PWV) is a marker of arterial stiffness. The aim of the present study was to compare PWV in patients with type 2 diabetes mellitus (T2DM) or obesity and healthy subjects in an outpatient setting. METHODS: A cross-sectional study was conducted in patients with obesity without T2DM (n = 37), T2DM without obesity (n = 40), T2DM plus ...
By Axelife SAS
-
National Toxicology Program workshop: role of environmental chemicals in the development of diabetes and obesity
The National Toxicology Program (NTP) is hosting this workshop on Jan. 11-13, 2011, because there is a growing body of research showing that chemicals in our environment may be contributing to diabetes and obesity worldwide, and that chemical exposures need to be considered along with nutrition and diet. Six chemical classes will be discussed at the workshop, including 1) arsenic and other ...
-
An Australian first for lupin genome project
Being conducted in collaboration with the Centre for Food and Genomic Medicine (CFGM) in Perth, WA, the three-year, $1.5 million project will enable researchers and breeders to accelerate lupin crop improvements such as drought tolerance, disease resistance and optimal flowering time. The research team will build upon established resources and employ powerful next-generation sequencing ...
-
NGOs call for EPA pesticide testing to be updated
The US Environmental Protection Agency have come under fire from leading NGOs for its outdated testing program of endocrine-disrupting chemicals. It is feared that the numerous holes in the current programme fail to detect many serious effects on human development. The Environmental Protection Agency is ready to start testing 67 pesticide ingredients for their possible endocrine disruption ...
-
GI Dynamics Appoints New Chief Executive Officer and Board of Directors
BOSTON — November 5, 2020 — GI Dynamics® Inc. (“GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has appointed Joseph Virgilio as president and chief executive officer of GI Dynamics, Mark Lerdal as chairman of the Board of Directors (“the Board”) and ...
-
Global warming may raise risk of Pacific fish poisoning
Rising sea temperatures caused by climate change may have contributed to a sharp increase in the incidence of a severe form of tropical fish poisoning afflicting people living on small islands around the Pacific region, a study has shown. A 60 per cent increase in the annual number of ciguatera poisoning cases in 18 Pacific island countries and territories between 1998–2008, compared with ...
By SciDev.Net
-
Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical ...
-
NIH/EPA Celebrate Children’s Health Month, 15 Years of Children’s Health Research
What: The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health (NIH), and U.S. Environmental Protection Agency (EPA) will host a conference, highlighting more than a decade of children’s research, and the impacts of creating a more sustainable and healthy environment for children. The conference, Protecting Children's Health for a ...
-
Sonic Incytes Successfully Completes Series A Raise of US$7.3M to Accelerate VelacurTM Commercialization
Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergies as the lead investor, and support from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels and INP Capital, as well as notable angel investors. The strategic equity ...
-
Stockholders Approve Delisting from the Official List
BOSTON and SYDNEY — 22 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of Stockholders on 21 June 2020 and, in accordance with ASX Listing Rule 3.13.2, is pleased to confirm that each of the ...
-
Conversion of June 2017 Convertible Note
BOSTON and SYDNEY — 15 July 2020 — GI Dynamics® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, advises that it has received a notice of conversion from Crystal Amber Fund Limited (“Crystal Amber”) (a Related Party for Australian Securities Exchange ...
-
Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives
Kallyope, a leading biotechnology company focused on identifying and developing therapeutics targeting the gut-brain axis, and Brightseed, creators of Forager®, a pioneering artificial intelligence platform that illuminates the connections between nature and human health, have entered a strategic research collaboration to screen plant compounds to identify and validate active agents that can ...
-
Dyve Biosciences Receives FDA Clearance to Begin Phase 2 Study of DYV-700 for Treatment of Acute Gout Pain
THOUSAND OAKS, Ca.--(BUSINESS WIRE)--Dyve Biosciences, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2 trial of DYV-700, the company’s topically administered therapeutic being developed to reduce the pain and duration of an acute gout flare. Dyve intends to initiate the Phase 2 trial, the TARGETS Study (NCT04130204), ...
-
Further Extension of Maturity Date of June 2017 Note and Financing Update
BOSTON and SYDNEY — 1 July 2020 — GI Dynamics® Inc. (ASX:GID) (”the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the extension of the maturity date of the Senior Secured Convertible Promissory Note issued to Crystal Amber Fund Limited (“Crystal ...
-
Novo Nordisk to Acquire Dicerna
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you